Literature DB >> 8431006

MICs and MBCs of clarithromycin against Mycobacterium avium within human macrophages.

N Mor1, L Heifets.   

Abstract

The inhibitory and bactericidal activities of clarithromycin were determined quantitatively against the intracellular populations of five Mycobacterium avium strains growing in monocyte-derived human macrophages. The MICs were 1.0 microgram/ml, and the MBCs ranged from 16.0 to 64.0 micrograms/ml; these values were similar to the MICs and MBCs found in broth cultures at pH 7.4 and were substantially lower than those found in broth cultures at pHs 6.8 and 5.0. Since the intracellular environment has a neutral or even an acidic pH, relatively low MICs and MBCs found in macrophage cultures can be associated with the fact that the drug concentrations in macrophages are substantially higher than those in the medium in which these cells are cultivated. Pretreatment of the macrophages 2 days prior to infection decreased the MICs twofold in comparison with results of experiments in which the drug was added to already infected macrophages.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8431006      PMCID: PMC187614          DOI: 10.1128/AAC.37.1.111

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  20 in total

1.  In vitro activities of several new macrolide antibiotics against Mycobacterium avium complex.

Authors:  S Naik; R Ruck
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

2.  A method for counting acid-fast bacteria.

Authors:  C C Shepard; D H McRae
Journal:  Int J Lepr Other Mycobact Dis       Date:  1968 Jan-Mar

3.  In vitro and in vivo activities of clarithromycin against Mycobacterium avium.

Authors:  P B Fernandes; D J Hardy; D McDaniel; C W Hanson; R N Swanson
Journal:  Antimicrob Agents Chemother       Date:  1989-09       Impact factor: 5.191

4.  Comparison of the intracellular activities of clarithromycin and erythromycin against Mycobacterium avium complex strains in J774 cells and in alveolar macrophages from human immunodeficiency virus type 1-infected individuals.

Authors:  D M Yajko; P S Nassos; C A Sanders; P C Gonzalez; W K Hadley
Journal:  Antimicrob Agents Chemother       Date:  1992-05       Impact factor: 5.191

5.  Effectiveness of ofloxacin against Mycobacterium tuberculosis and Mycobacterium avium, and rifampin against M. tuberculosis in cultured human macrophages.

Authors:  A J Crowle; N Elkins; M H May
Journal:  Am Rev Respir Dis       Date:  1988-05

6.  Comparison of 15 laboratory and patient-derived strains of Mycobacterium avium for ability to infect and multiply in cultured human macrophages.

Authors:  A J Crowle; A Y Tsang; A E Vatter; M H May
Journal:  J Clin Microbiol       Date:  1986-11       Impact factor: 5.948

7.  Clofazimine and other rimino-compounds: minimal inhibitory and minimal bactericidal concentrations at different pHs for Mycobacterium avium complex.

Authors:  P J Lindholm-Levy; L B Heifets
Journal:  Tubercle       Date:  1988-09

8.  Selective medium for the isolation and enumeration of Mycobacterium avium-intracellulare and M. scrofulaceum.

Authors:  K L George; J O Falkinham
Journal:  Can J Microbiol       Date:  1986-01       Impact factor: 2.419

9.  Comparative antimycobacterial activities of difloxacin, temafloxacin, enoxacin, pefloxacin, reference fluoroquinolones, and a new macrolide, clarithromycin.

Authors:  E A Gorzynski; S I Gutman; W Allen
Journal:  Antimicrob Agents Chemother       Date:  1989-04       Impact factor: 5.191

10.  Response in the hindfoot pad and popliteal lymph node of C57BL mice to infection with Mycobacterium marinum.

Authors:  N Mor; I Lutsky; L Levy
Journal:  Isr J Med Sci       Date:  1981-04
View more
  19 in total

1.  Bactericidal activities of the pyrrole derivative BM212 against multidrug-resistant and intramacrophagic Mycobacterium tuberculosis strains.

Authors:  D Deidda; G Lampis; R Fioravanti; M Biava; G C Porretta; S Zanetti; R Pompei
Journal:  Antimicrob Agents Chemother       Date:  1998-11       Impact factor: 5.191

Review 2.  Susceptibility testing of Mycobacterium avium complex isolates.

Authors:  L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1996-08       Impact factor: 5.191

3.  Reporter gene technology to assess activity of antimycobacterial agents in macrophages.

Authors:  T M Arain; A E Resconi; D C Singh; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-06       Impact factor: 5.191

4.  The phagosomal environment protects virulent Mycobacterium avium from killing and destruction by clarithromycin.

Authors:  C Fréhel; C Offredo; C de Chastellier
Journal:  Infect Immun       Date:  1997-07       Impact factor: 3.441

5.  A bone marrow-derived murine macrophage model for evaluating efficacy of antimycobacterial drugs under relevant physiological conditions.

Authors:  P S Skinner; S K Furney; M R Jacobs; G Klopman; J J Ellner; I M Orme
Journal:  Antimicrob Agents Chemother       Date:  1994-11       Impact factor: 5.191

6.  Effects of clarithromycin and rifabutin alone and in combination on intracellular and extracellular replication of Mycobacterium avium.

Authors:  N Mor; J Vanderkolk; N Mezo; L Heifets
Journal:  Antimicrob Agents Chemother       Date:  1994-12       Impact factor: 5.191

Review 7.  Clarithromycin. A review of its pharmacological properties and therapeutic use in Mycobacterium avium-intracellulare complex infection in patients with acquired immune deficiency syndrome.

Authors:  L B Barradell; G L Plosker; D McTavish
Journal:  Drugs       Date:  1993-08       Impact factor: 9.546

Review 8.  Animal and cell-culture models for the study of mycobacterial infections and treatment.

Authors:  I M Orme; A D Roberts; S K Furney; P S Skinner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1994-11       Impact factor: 3.267

9.  In vitro susceptibility of Mycobacterium ulcerans to clarithromycin.

Authors:  F Portaels; H Traore; K De Ridder; W M Meyers
Journal:  Antimicrob Agents Chemother       Date:  1998-08       Impact factor: 5.191

10.  Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice.

Authors:  M J Hickey; T M Arain; R M Shawar; D J Humble; M H Langhorne; J N Morgenroth; C K Stover
Journal:  Antimicrob Agents Chemother       Date:  1996-02       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.